Abstract | BACKGROUND: METHOD: Seventeen DSM-IV anorexia nervosa subjects hospitalized between May 1999 and October 2000 were enrolled in open-label treatment with olanzapine for up to 6 weeks. Baseline weight and symptoms were compared to patients' status at the end of treatment. RESULTS:
Olanzapine administration was associated with a significant reduction in depression, anxiety, and core eating disorder symptoms, and a significant increase in weight. A comparison with our historical data suggests that subjects in this study had a significantly greater decrease in depression. CONCLUSION: These data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa. However, a controlled trial is necessary to demonstrate that olanzapine is efficacious.
|
Authors | Nicole C Barbarich, Claire W McConaha, Jill Gaskill, Maria La Via, Guido K Frank, Sarah Achenbach, Katherine H Plotnicov, Walter H Kaye |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 65
Issue 11
Pg. 1480-2
(Nov 2004)
ISSN: 0160-6689 [Print] United States |
PMID | 15554759
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Benzodiazepines
- Olanzapine
|
Topics |
- Adult
- Anorexia Nervosa
(drug therapy, psychology)
- Antipsychotic Agents
(adverse effects, pharmacology, therapeutic use)
- Behavioral Symptoms
(drug therapy)
- Benzodiazepines
(adverse effects, pharmacology, therapeutic use)
- Female
- Humans
- Olanzapine
- Treatment Outcome
- Weight Gain
(drug effects)
|